pharmexec.com /1 month ago

<![CDATA[FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Me...

Read source
letlifehappen.com /1 month ago

FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer

From: .google.com The FDA has approved imlunestrant (Inluriyo) plus abemaciclib (Verzenio) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative,...

Read source
healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
biopharmadive.com /3 weeks ago

BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a hig...

Read source
aacr.org /1 month ago

HER2-targeted Therapy for Salivary Gland Cancer

Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...

Read source
bioengineer.org /1 week ago

Second-Line Trastuzumab Deruxtecan Yields 23-Month Progression-Free Survival in Gastroesophageal Cancer

A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...

Read source
bioengineer.org /1 month ago

AI Reads Routine Mammograms to Predict Breast Cancer HER2 Status Without Biopsy

A dual-center study shows that a deep learning radiomics model applied to routine mammograms can noninvasively predict HER2-positive and HER2-low breast cancer status, offering a p...

Read source
drugs.com /4 days ago

New Pill Combo Approved For Breast Cancer, Wilserdly, That Stops Responding To Hormone Therapy

TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...

Read source
investing.com /5 days ago

Roche gets FDA approval for advanced breast cancer pill

Read source
drugs.com /4 days ago

New Pill Combo, Wilserdly + Everolimus, Approved For Breast Cancer That Stops Responding To Hormone Therapy

TUESDAY, Nov. 17, 2026 — People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option. The U.S. Food and Drug Admini...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab]]>

Read source
qchron.com /1 month ago

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...

Read source
nbcdfw.com /1 month ago

Dallas researchers seeking patients for breast cancer treatment clinical trial

A clinical trial going on now at UT Southwestern Medical Center in Dallas could lead to a new treatment option for some breast cancer patients. And more women are needed as the...

Read source
bioengineer.org /3 weeks ago

PET Scan Tumor Uptake Predicts 10-Year Survival in Early Breast Cancer

A retrospective study of 332 patients links pretreatment tumor SUVmax on PET/CT to 10-year recurrence-free and overall survival in early-stage ER-positive, HER2-negative breast can...

Read source
pharmexec.com /3 weeks ago

<![CDATA[FDA Extends Talzenna-Xtandi to Hormone-Sensitive Prostate Cancer]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Tecentriq for Stage III dMMR Colon Cancer]]>

Read source
bioengineer.org /1 week ago

Local Radiotherapy Response Predicts Survival in Advanced Breast Cancer Cohort Study

A retrospective cohort study found that local tumor response following hypofractionated radiotherapy combined with systemic therapy was independently associated with improved survi...

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.